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Anti-fibroblast antibodies detected by cell-based ELISA in
systemic sclerosis enhance the collagenolytic activity and
matrix metalloproteinase-1 production in dermal fibroblasts
S. Fineschi1, F. Cozzi2, D. Burger1, J.-M. Dayer1, P. L. Meroni3 and C. Chizzolini1
Objectives. Antibodies binding to the surface of fibroblasts (anti-fibroblast antibodies: AFA) have been described in systemic sclerosis
(SSc). We aimed to assess the effect of AFA on extracellular matrix (ECM) turnover and whether AFA were associated with anti-
topoisomerase-I antibody.
Methods. IgG were purified from AFA-positive and AFA-negative sera selected within 20 SSc and 20 healthy individuals, and tested on
normal dermal fibroblasts, at protein and mRNA level, for their capacity to induce collagen deposition or degradation.
Results. Fibroblasts stimulated with AFA-positive but not with AFA-negative and control IgG showed an increased capacity to digest collagen
matrix and produce metalloproteinase-1 (MMP-1) while their production of total collagen, type I collagen and tissue inhibitor
of metalloproteinase-1 (TIMP-1) was unaffected. The steady-state mRNA levels of MMP-1, COL1A1 and TIMP-1 paralleled the protein
levels. AFA-positive IgG did not induce Smad 2/3 phosphorylation, indicating that this transforming growth factor- signalling pathway was
not involved. IL-1 and tumour necrosis factor (TNF) neutralization did not reverse the enhanced production of MMP-1, suggesting a direct
effect of AFA on fibroblasts. Finally, anti-topoisomerase-I antibodies were present in 11 of 12 AFA-negative IgG, and an anti-topoisomerase-I
monoclonal antibody failed to enhance MMP-1 production, thus indicating a lack of correlation between AFA and anti-topoisomerase-I
antibody.
Conclusions. These results indicate that SSc antibodies binding to fibroblasts enhance matrix degradation and MMP production events that
may favour inflammation but do not directly impact on fibrosis development.
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Introduction
Systemic sclerosis (SSc) is a disorder of unknown origin char-
acterized by the presence of autoantibodies, fibroproliferative
vasculopathy and excessive extracellular matrix (ECM) deposi-
tion, leading to fibrosis of the skin and internal organs [1].
Fibroblasts play a central role in ECM production and degrada-
tion [2]. They synthesize ECM molecules, including several
collagens (particularly type I collagen, the most abundant in the
skin), express degrading enzymes such as matrix metalloprotein-
ases (MMPs) and tissue inhibitors of MMP (TIMPs) [3, 4]. SSc
fibroblasts differ from normal fibroblasts in many respects as they
produce more collagen [5], constitutively overexpress connective
tissue growth factor (CTGF) which promotes fibroblast prolifera-
tion and ECM production [6], as well as -smooth muscle actin
(-SMA) [7]. Transforming growth factor- (TGF-) stimulates
matrix production and induces its own synthesis and that of
CTGF [8]. Smads are among the intracellular effectors of TGF-,
the principal mediator of tissue fibrosis [9]. In scleroderma
fibroblasts, Smad3 and Smad4 show nuclear localization and
elevated levels of phosphorylated Smad2/3 in the absence of
exogenous TGF-, suggesting a constitutive activation of the Smad
pathway [9].
Antibodies against ubiquitous cellular self-components are
characteristically present in more than 90% of SSc patients and
are associated with different clinical subsets [10]. In addition,
autoantibodies that specifically bind to fibroblasts have been
described. We reported the presence of anti-fibroblast antibodies
(AFA), capable of binding the fibroblast cell surface and induce
a pro-adhesive and pro-inflammatory phenotype, up-regulating
the expression of intercellular adhesion molecule 1 (ICAM-1)
and IL-6 [11] in more than 40% of SSc patients. Others have found
AFA in SSc patients with anti-topoisomerase-I antibodies, mostly
affected by the diffuse form of the disease, and shown that
they strongly correlated with anti-topo-I Ab [12, 13]. Of interest,
IgG of SSc individuals with pulmonary artery hypertension (PAH)
were shown to recognize fibroblast components distinct from those
with primary PAH [14]. In addition, non-ubiquitous antigen
target of autoantibodies with the potential to modify ECM
turnover include fibrillin-1, a non-structural matrix component
and platelet-derived growth factor (PDGF) receptor [15, 16].
Stimulatory antibodies to PDGF-R are not restricted to SSc but
have also been found in chronic graft vs host disease [17].
Furthermore, fibroblast activation has also been associated with
antibodies which cross-recognize the human CMV-derived protein
UL94 and the adhesion self-molecule NAG-2 [18, 19].
The contribution of AFA to pathogenic events leading to
fibrosis in SSc is still debated. In the present study, we asked
the question whether AFA could impact on ECM turnover.
Our findings indicate that SSc AFA-positive IgG preferentially
induce ECM degradation rather than deposition, in a tumour
necrosis factor (TNF) and IL-1-independent manner. Thus,
a subset of SSc patients harbours autoantibodies that bind to
fibroblasts and restrain their potential of ECM deposition.
Materials and methods
Patients and controls
Twenty SSc patients (17 women and 3 men, mean S.D. age
49 11 yrs) and 20 age- and sex-matched healthy blood donors
were enrolled in the study. All patients fulfilled the American
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College of Rheumatology criteria for SSc classification [20], and
all but one were anti-topoisomerase-I antibodies positive.
The only anti-topo-I-negative had a nucleolar ANA aspect.
None had anti-centromere antibodies. Peripheral blood and skin
biopsies were obtained from patients and controls after informed
written consent according to the Declaration of Helsinki.
The study was approved by the Ethics Committee of the
Geneva University Hospital.
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), non-essential
amino acids solution 100, sodium pyruvate, penicillin and
streptomycin were obtained from GIBCO (Invitrogen); -keto-
glutaric acid, -amino propionitrile and fetal calf serum (FCS)
from Sigma (St Louis, MO, USA); recombinant human TGF-1
(rhTGF-1), recombinant human interleukin-1- (rhIL-1), anti-
intercellular adhesion molecule 1 (ICAM-1) monoclonal antibody,
recombinant human TNF- (rhTNF-) from R&D System
(Minneapolis, MN, USA); mouse anti-topo-I monoclonal anti-
body from Immunovision, (Springdale, AR, USA); recombinant
human interleukin-1 receptor antagonist-1 (rhIL-1Ra) and
soluble TNF receptor p75 (anti-TNF-) from Amgen (Boulder,
CO, USA); Limulus Amebocyte Lysate Endochrome, multitest
vials for endotoxin from Charles River Endosafe (Charleston,
SC, USA).
Culture conditions
Skin biopsies were taken from the forearm of normal individuals
under local anaesthesia. Fibroblasts were grown in 100mm
culture dishes at 378C in 5% CO2 humidified atmosphere
in DMEM with 100U/ml penicillin, 100g/ml streptomycin,
2mM glutamine, 1% non-essential amino acids and 1% sodium
pyruvate supplemented with 10% FCS, and used from passages
3 to 10.
Enzyme-linked immunosorbent assay (ELISA)
SSc sera were screened for the presence of anti-topo-I Ab by
ELISA (QuantaLiteTM Scl-70, Inova Diagnostic, San Diego,
USA). Total IgG were purified from 12 SSc sera (eight AFA-
positive and four AFA-negative) and eight normal human sera
(NHS) by protein G-sepharose chromatography (Pharmacia,
Uppsala, Sweden). To detect AFA and ICAM-1 expression on
the surface of fibroblasts, we performed a cell-based ELISA as
described [11]. Sera and IgG were tested in triplicates. As positive
control, fibroblasts were stimulated by TNF (10 ng/ml) and IL-1
(50 ng/ml).
Type I collagen, MMP-1 and TIMP-1 protein
production assay
Fibroblasts were plated in 96-well trays at 2 104 cells/well and
serum-starved overnight before being cultured with IgG, or
cytokines, or medium alone for an additional 48 h in medium
supplemented with 1% FCS, 25g/ml L-ascorbic acid, 3.4g/ml
-ketoglutaric acid and 50g/ml -amino propionitrile in order
to favour normal collagen fibrillogenesis [21]. When required,
IL-1Ra (2g/ml) and anti-TNF (108M) were added 1 h before
IL1- (10 ng/ml), TNF (10 ng/ml) or IgG (300g/ml). The
supernatants were collected and stored at 208C until protein
determination. All experimental conditions were made in tripli-
cate. The ELISA for TIMP-1 (R&D) and pro-MMP-1 (Binding
Site, Birmingham, UK) and the RIA for the determination of
N-terminal propeptide of type I procollagen (PINP-1) (Orion
Diagnostica, Espoo, Finland) were performed according to the
manufacturer’s instructions. Total collagens was assessed on
supernatants of fibroblasts cultured for 24, 48 and 72 h in
100mm dishes with DMEM supplemented with 25g/ml
vitamin C, in the absence of FCS, by the Syrcol TM assay
(Biocolor Ltd, New Townabbey, UK).
Collagenase assay
Collagenase activity was assessed by ELISA on type I calf skin
collagen (Sigma) coated for 7 days on to 96-well plates, as described
[22]. Samples were activated with trypsin 100g/ml for 20min at
378C, to convert latent collagenase into its active form, followed by
a 5-fold excess addition of soybean trypsin inhibitor (Worthington,
Freehold, NJ, USA) and tested in triplicate. The undigested
collagen was detected with an anti-type I collagen mouse
monoclonal antibody (Calbiochem, La Jolla, CA, USA) followed
by alkaline phosphatase-labeled anti-mouse IgG sheep antibody
(Cappel, West Chester, PA, USA). One unit of collagenase was
defined as the activity that solubilizes 1g of collagen in 1min.
Western blotting
Fibroblasts cultured in serum-free medium for the indicated times
under different experimental conditions were lysed in lysis buffer
containing protease inhibitors. Twenty micrograms of total
protein extracts were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electophoresis under reducing conditions and
electroblotted on to nitrocellulose membrane (HybondTM ECLTM
Amersham Pharmacia Biotech, UK). Blots were incubated with
antibodies against phospho Smad 2/3 (ser 465/467) (Cell Signaling,
Beverly, MA, USA) and -tubulin (Sigma). HRP-conjugated
antisera were used to reveal primary binding and detected by
chemiluminescence using the ECL system (Amersham).
Indirect immunoflurescence (IIF)
Dermal fibroblasts were grown on glass coverslips to 80%
confluence, in serum-free conditions. Cells were fixed with 4%
paraformaldehyde for 30min at room temperature, made perme-
able or not in 0.1% saponin, 1% BSA in PBS for 30min and
subsequently incubated with mouse anti-topo-I mAb (20g/ml) or
AFA-positive IgG, AFA-negative IgG or NHS IgG (300g/ml)
for 1 h, followed by anti-human IgG FITC (Inova Diagnostic,
San Diego, CA, USA) or Alexa Fluor 488 goat anti-mouse IgG
(Molecular Probe, Eugene, OR, USA). The nonspecific binding
was assessed by testing the binding of the secondary antibody alone
(anti-human and anti-mouse). Slides were mounted in Vectashield
fluorescence medium (Vector Laboratories, Burlingame, CA,
USA), and images were acquired using a Zeiss fluorescence
microscope equipped with AxioCam Color CCD Camera.
Determination of mRNA levels of COL1A1, MMP-1,
MMP-9, TIMP-1, CTGF and -SMA
Total RNA of fibroblasts, starved in serum-free medium over-
night and cultured for 24, 48 and 72 h with IgG and cytokines, was
isolated by RNeasy Mini Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer’s instructions. Samples were
homogenized on QIA shredder columns (Qiagen) before RNA
isolation, and treated with RNAse-free DNAse set (Qiagen) to
remove DNA during RNA purification. The quality of RNA was
checked by the Agilent Technologies 2100 Bioanalyzer (version
A02.12 SI 292). The mRNA levels were determined by real-time
quantitative RT-PCR. The TaqMan assay reagents (Universal
PCR Master Mix Buffer) and primers for human MMP-1,
MMP-9, TIMP-1, CTGF, -SMA, COLA1A, GADPH and 18S
rRNA were from by Applied Biosystem (Foster City, CA, USA).
The primers and probes for human eukaryotic translation
elongation factor 1-1 (EEF1A1) (forward, 50-AGCAAAAATG
ACCCA CCAATG-30 and reverse, 50-GGCCTGGATGGTTCA
GGATA-30), and human transferrin receptor (TFRC) (forward,
50-CATTTGTGAGGGATCTGAACCA-30 and reverse, 50-CGA
GCAGAATACAGCCACTGTAA-30) were provided by the
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Genomic Platform, NCCR Frontiers in Genetics, University of
Geneva. The GeNorm program was used to select the two best
housekeeping genes among GAPDH, 18S, EEF1A1, TFRC and
TBC, based on stability in response to experimental treatments
[23]. The results were normalized to the geometric mean of two
housekeeping genes (EEF1A1 and TFRC). PCR was performed in
triplicate using ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystem) in a final volume of 10l. The thermal cycler
conditions were the following: 508C for 2min, 958C for 10m, then
50 cycles of 958C for 15 s and 608C for 1m. The cDNA synthesis
reaction without RNA or cDNA synthesis reaction without
reverse transcriptase were used as controls and were negative for
amplification products.
Statistical analysis
Student’s t-test was used to analyse differences between the two
groups. A one-way ANOVA test (Dunnett method) was used to
assess the differences among groups. A P-value 0.05 was
considered statistically significant.
Results
Antifibroblast antibody identification
Serum samples from 20 SSc patients whose clinical characteristics
are reported in Table 1 and 20 healthy individuals (NHS) were
tested for their capacity to bind human dermal fibroblasts in a cell-
based assay [11]. Binding to fibroblasts was observed in 8 of 20 SSc
and in none of the 20 healthy control sera (Table 1). AFA-positive
had less immunosuppressive therapy than AFA-negative individ-
uals. Two of eight AFA-positive had low-dose prednisone
(<10mg/day) for 6 months, while nine of twelve AFA-negative
patients had low-dose prednisone from 6 months to 7 yrs (Table 1).
IgG purified from SSc patients was defined AFA-positive when
binding to fibroblasts was observed, and AFA-negative when it
was not. Total IgG was purified by protein G-sepharose
chromatography from eight AFA-positive, four AFA-negative
and eight NHS. All eight AFA-positive IgG showed a dose-
dependent binding to fibroblasts, with half-maximal binding at the
concentration of 59.7 6.4g/ml; in contrast AFA-negative IgG,
NHS IgG and one preparation of commercial human IgG
(Redimune, Behring AG) did not show significant binding. In
all cases, IgG binding resulted in ICAM-1 up-regulation, while
undetectable binding to fibroblasts resulted in the lack of ICAM-1
up-regulation, as reported previously [11]. Experiments performed
in the presence of polymyxin B gave comparable results, and in all
IgG preparations endotoxin levels were below the threshold of
detection (<0.25EU/ml) (data not shown).
AFA-positive IgG enhance MMP-1 production and
collagenolytic activity in dermal fibroblasts, but not
type I collagen and TIMP-1
We then assessed whether IgG could affect the balance between
ECM production and degradation. While total collagen produc-
tion was not modified, the collagenolytic activity of fibroblasts
cultured in the presence of AFA-positive but not AFA-negative
IgG was markedly enhanced (P< 0.05) (Fig. 1A and B). Notably,
AFA-positive IgG was as potent as 10 ng/ml of TNF in inducing
fibroblast collagenolytic activity (Fig. 1B). To substantiate these
findings, we determined the amount of MMP-1 and its inhibitor
TIMP-1 in addition to type-I collagen (PINP-1) produced by
fibroblasts exposed to IgG preparations. Consistently, AFA-
positive but not AFA-negative nor NHS IgG enhanced in a dose-
dependent manner the production of MMP-1, while TIMP-1
and PINP-1 were not affected (Fig. 1C–H). At 300 g/ml,
AFA-positive IgG increased by 3-fold MMP-1 production
(P< 0.05) (Fig. 1F). Of interest, in the same culture conditions,
TGF- used as pro-fibrotic control enhanced PINP-1 and TIMP-1
and decreased MMP-1 production (Fig. 1C, E and G). Thus,
AFA-positive IgG specifically favour ECM degradation.
AFA-positive IgG increase steady-state mRNA levels
of MMP-1, MMP-9, but not those of COL1A1, CTGF,
-SMA and TIMP-1
To determine whether the changes observed at the protein level
were paralleled by changes in gene transcription, we tested by
quantitative RT-PCR whether IgG would induce changes in
COL1A1, MMP-1 and TIMP-1 mRNA steady-state levels. While
MMP-1 mRNA was significantly increased by AFA-positive IgG,
with a peak at 24 h (Fig. 2B), COL1A1 and TIMP-1 were not
(Fig. 2A). Similar results were obtained by northern blot and
ribonuclease protection assay (data not shown). The gelatinase
MMP-9 mRNA was also increased in fibroblasts by AFA-positive
IgG (Fig. 2C), whereas mRNA levels of CTGF and -SMA,
which are present in pro-fibrotic condition and over expressed in
SSc fibroblasts, were not modified (Fig. 2D and E). AFA-negative
and NHS IgG did not affect transcription in any of the genes
studied (Fig. 2A–E). In conclusion, AFA-positive IgG increases
the mRNA steady-state levels of MMP-1 and MMP-9, but does
not affect those of genes associated with fibrosis such as type-I
collagen, TIMP-1, CTGF and -SMA.
AFA-positive IgG does not induce Smad 2/3 phosphorylation
Since there is increasing evidence that alterations in the TGF-
signalling pathway and in particular in the levels of Smad 2/3 may
contribute to abnormal ECM deposition and it has been reported
that scleroderma fibroblasts display an enhanced phosphorylation
of Smad 2/3, also in the absence of TGF- [9], we tested the
expression of phospho-Smad 2/3 by western blotting. AFA-
positive IgG did not induce any detectable Smad 2/3 phosphor-
ylation, in contrast to TGF-, used as positive control (Fig. 3).
This finding is consistent with the lack of a pro-fibrotic activity of
AFA-positive IgG on fibroblasts.
MMP-1 induction by AFA-positive IgG is not mediated
by TNF or IL-1
TNF and IL-1 are key regulators of inflammatory responses and
are potent inducers of MMPs [24, 25]. To test the hypothesis that
TABLE 1. Clinical characteristics of SSc patients and autoantibodies
N Age Gender
Disease
duration
(months)
Form of
SSc
Lung
involvement
Anti-
topo-I Therapy AFA
1 30 F 4 dSSc No þ None þ
2 24 F 43 lSSc No þ Iloprost þ
3 61 F 240 dSSc Yes þ PRED þ
4 38 F 36 dSSc Yes þ None þ
5 42 F 48 dSSc Yes þ None þ
6 52 F 12 lSSc Yes þ Iloprost þ
7 43 F 6 lSSc No þ Iloprost þ
8 50 F 72 dSSc Yes þ PRED, Iloprost þ
9 57 M 9 dSSc Yes þ PRED, Iloprost 
10 58 F 4 dSSc No þ PRED, MTX 
11 43 F 12 dSSc Yes þ None 
12 58 F 36 dSSc No þ PRED 
13 50 F 60 lSSc Yes þ None 
14 47 F 48 dSSc No  PE, D-Penicillamine 
15 68 M 6 dSSc Yes þ MMF, PRED, CYC 
16 63 M 11 dSSc Yes þ PRED, Iloprost 
17 54 F 63 lSSc Yes þ PRED, AZA 
18 48 F 36 lSSc Yes þ PRED 
19 58 F 115 lSSc Yes þ PRED 
20 41 F 108 dSSc No þ PRED 
Disease duration: since first SSc symptom whether Raynaud or other. Type of SSc: limited
cutaneous form (lSSc), diffuse cutaneous form (dSSc). Therapy: AZA, azathioprine; CYC,
cyclophosphamide; PE, plasma exchange; PRED, prednisone; MMF, mycophenolate mofetil;
MTX, methotrexate.
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AFA-positive IgG could induce MMP-1 indirectly by eliciting the
autocrine production of IL-1 or TNF, the activity of AFA-
positive IgG was assessed in the presence of IL-1Ra and of anti-
TNF. While IL-1Ra abrogated MMP-1 production induced by
IL-1 and anti-TNF that is induced by TNF (Fig. 4B), neither of
these two inhibitors affected MMP-1 induced by AFA-positive
IgG (Fig. 4A). This strongly indicates that AFA-positive IgG does
not act by eliciting an autocrine production of IL-1 or TNF.
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FIG. 1. Effect of AFAþIgG, AFAIgG, NHS IgG and IVIg on type I collagen,MMP-1 and TIMP-1 proteins. (A) Total collagen detected bySyrcol assay. (B) Collagenase activity.
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Anti-topoisomerase-I antibodies do not bind to fibroblast
surface and do not induce MMP-1 production
Direct binding of anti-topo-I auto-Ab to the cell surface of
fibroblasts that induces monocyte adhesion and activation has
been reported in patients with SSc [12, 13]. To test the possibility
that topo-I may be recognized by AFA, we screened AFA-positive
and AFA-negative SSc sera for their anti-topo-I reactivity. Eight
of eight AFA-positive sera and 11 of 12 AFA-negative sera were
positive for anti-topo-I auto-Ab (Table 1), thus indicating
a dissociation for the presence of AFA-positive and anti-topo-I
IgG within individual sera. We further assessed whether a mouse
anti-topo-I mAb could bind to fibroblast cell surface and induce
MMP-1 production. The murine anti-topo-I mAb displayed
a nuclear fluorescence in fibroblasts made permeable, but failed
to bind the plasma membrane in intact cells (Fig. 5A, panels 3
and 4). This was distinctly different from AFA-positive IgG that
showed a nuclear fluorescence in cells made permeable and
a surface fluorescence in intact fibroblasts (Fig. 5A, panels 2
and 3). The lack of binding of anti-topo-I mAb on fibroblast
surface up to a concentration of 100g/ml was confirmed in a
cell-based ELISA (data not shown). Moreover no ICAM-1
(Fig. 5B) and MMP-1 (Fig. 5C) regulation was observed in the
presence of anti-topo-I mAb, in contrast to AFA-positive IgG.
Overall, these results indicate that antibodies directed against
topo-I differ from AFA-positive IgG in terms of binding to
fibroblasts and biological functions.
Discussion
The pathogenesis of SSc remains poorly understood and no
unitary theory has been developed to clarify the interactions
between autoimmunity and fibrosis. In this study, we addressed
the question whether autoantibodies binding to fibroblast surface
(AFA) may induce changes in fibroblast metabolism affecting
ECM deposition. Our data strongly indicate that AFA enhance
the collagenolytic activity of fibroblasts by favouring MMP-1 and
MMP-9 gene transcription and MMP-1 production without
affecting their production of TIMP-1 and of collagens including
type I collagen. In addition, AFA failed to induce CTGF and
-SMA gene transcription, and Smad 2/3 signalling, currently
considered markers of fibroblasts actively involved in ECM
deposition. In the search for molecular mechanisms triggered by
AFA in inducing MMP-1, we explored the possible contribution
of IL-1 and TNF. Indeed, IL-1 and TNF are known to be potent
inducers of MMPs [24, 25] and autocrine production of these
cytokines by AFA-activated fibroblasts could explain our find-
ings. In addition, while direct testing of our IgG preparations
failed to detect IL-1 and TNF, we could not exclude the
contaminating presence of minute, but biologically active,
amounts of these cytokines. The results obtained with biological
agents capable of neutralizing IL-1 and TNF, however, proved
that these cytokines were not involved in MMP-1 production in
our experiments. Thus, these findings suggest a direct effect of
AFA on fibroblasts.
We have not yet identified the autoantigen(s) recognized
by AFA. Several, different, non-ubiquitous autoantigens
have recently been reported to be recognized by IgG from SSc
patients. Of interest, antibodies recognizing fibrillin-1 have
been shown to activate fibroblasts and MMP-1 was among the
up-regulated genes [15]. At variance with our findings, however,
fibrillin-1-specific IgG also induced collagen gene up-regulation
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in a TGF--dependent manner [15]. Furthermore, autoantibodies,
binding to the PDGF-R, have been shown to activate fibroblasts,
favouring collagen deposition [16]. Antibodies cross-recognizing
UL94, a CMV peptide, and NAG-2, an adhesion molecule
expressed on fibroblast surface, also favoured collagen synthesis
[18, 19]. Thus, a large panel of autoantibodies with presumed
different specificities, present in SSc sera, is being characterized
and appear to induce a variety of non-overlapping fibroblast
responses, which may participate to events relevant to SSc
pathogenesis. Within this variety, the anti-fibroblasts antibodies
we detect by cell-based ELISA are enriched for IgG with
predominant collagenolytic activity. In this respect, it is interesting
to note that beside their involvement in matrix digestion, MMP
induced by AFA could modulate inflammation by enhancing or
dampening the biological activity of several mediators, including
cytokines and chemokines [26]. Modulation of inflammation may
then impact on the development of fibrosis [27].
Consistently with a lack of enhanced collagen deposition, we
could not detect SMAD phosphorylation in fibroblasts stimulated
by AFA. In preliminary experiments, we observed that AFA were
activating other intracellular signalling pathways including the
MAP kinase ERK 1/2, and the transcription factors NF-B and
AP-1.
The samples we tested were from patients with heterogeneous
clinical presentations and different disease duration. It is also
possible that previous treatment had an impact on AFA levels.
However, the biological activities of IgG were robust and
consistent across the various assays preformed (present article
and Fineschi et al., manuscript in preparation). In our hands, the
most important characteristic for predicting biological activity
was the capacity of IgG to bind to fibroblast surface as detected
by cell-based ELISA. Indeed, binding was always accompanied by
substantial biological activity, while no binding correlated with no
or very low biological activity. In this respect, it is interesting to
note that most of the IgG we tested were from individuals who
were anti-topo-I-positive, but binding to fibroblasts did not
correlate with anti-topo-I positivity. In addition, a mouse anti-
topo-I mAb failed to induce MMP-1 or ICAM-1 in exposed
fibroblasts, thus strongly suggesting that anti-topo-I Ab are
not directly involved in fibroblast activation, while they may, as
0
0.4
0.8
1.2
AFA+IgG
M
M
P-
1 
(mg
/m
l)
0
1
2
3
4
5
M
M
P-
1 
(mg
/m
l)
Medium AFA+IgG
+ IL-1Ra
AFA+IgG
+ anti-TNF
TN
F
Me
diu
m
IL
-1
b
IL
-1
b+
IL
-1
Ra
IL
-1
Ra
TN
F+
an
ti-
TN
F
an
ti-
TN
F
A
B
FIG. 4. AFAþ IgG induce MMP-1 in an IL-1 and TNF-independent manner.
The bars represent the mean S.E.M.of 3 AFAþ IgG, and 3 NHS IgG. (IL1-
10ng/ml, IL-1Ra 2g/ml, TNF 10 ng/ml, anti-TNF- 108M and IgG 300g/ml).
The inhibitors were added 1 h before the agonist. Proteins were determined by
ELISA after 48 h of culture.
C
0
1
2
3
4
Medium 100 20 4 0.8 AFA+IgG
M
M
P-
1 
x-
fo
ld
 m
ed
iu
m
 v
al
ue
anti-topo-I mAb (mg/ml)
B
0
0.200
0.400
0.600
0.800
1.000
1.200
1.400
1.600
TNF AFA+IgG 100 20 4 0.8 medium
IC
AM
-1
 (O
D)
anti-topo-I mAb(mg/ml)
A AFA+IgG
AFA+IgG
anti-topo-I mAb
anti-topo-I mAb
Cells made
permeable
Cells not
permeable
1
2
3
4
FIG. 5. Anti-topo-1 antibody do not bind to the surface of fibroblasts and do not
induce ICAM-1 and MMP-1 up-regulation. (A) Indirect immunofluorescence
microphotographs (original magnification 630). In the upper panels, fibroblasts
were made permeable and then incubated an hour with AFAþIgG (300g/ml) and
anti-topo-I (20g/ml). In the lower panels, fibroblasts were not made permeable.
Anti-topo-I mAb gives only a nuclear staining. AFAþ IgG, which is also anti-topo-I-
positive, gives both nuclear and plasma-membrane staining depending on whether
cells were permeable or not. One of the three independent experiments. (B) ICAM-
1 expression tested in cell-based ELISA on fibroblasts cultured for 24 h.
Mean S.D. of triplicates of a representative experiment of two. (C) MMP-1
ELISA on supernatants of fibroblasts cultured 48 h with AFAþ IgG (300g/ml) and
anti-topo-ImAb. One representative experiment of three.
1784 S. Fineschi et al.
suggested by others, participate to monocyte recruitment leading
to a cascade of events relevant to SSc pathogenesis [12, 13].
In conclusion, our data concur with those reported by others in
indicating that anti-fibroblast antibodies may not only be an
epiphenomenon resulting from the loss of tolerance, but may have
pathogenic relevance. Thus, AFA may participate, at least in
a subset of SSc individuals, to events that indirectly, by favoring
inflammation, or directly, by reprogramming fibroblast gene
expression, result in pathological changes characteristic of SSc.
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Rheumatology key messages
 Antibody binding to fibroblast surface in SSc sera activate
fibroblast inflammatory responses.
 Humoral immunity may participate in pathogenetic events relevant
to SSc development.
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